News | August 16, 2021
Orchid Pharma reports net loss of Rs 30.90 cr in Q1FY22
EPS for the period at Rs. (7.57)
EPS for the period at Rs. (7.57)
The hospital chain aggressively embarks on digitisation and is e-health ready
The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
EPS at Rs 32.19
Substantial reduction in losses
Subscribe To Our Newsletter & Stay Updated
